Shopping Cart 0
Cart Subtotal
USD 0

Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic personal care ingredients. It also provides custom development and custom manufacturing services to its clients. Lonza's client base includes professionals in the biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; distributors; formulators and service companies. The company's key markets include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care industries. It operates several manufacturing and research and development (R&D) facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd (LONN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Lonza to Acquire Mammalian Manufacturing Site from Shire 16

Capsugel Acquires Ionic Liquids Technology from Monash University 17

InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18

Venture Financing 19

Odyssey Thera Raises USD 3 Million In Venture Financing 19

Private Equity 20

Kainos Capital Acquires InterHealth Nutraceuticals 20

Partnerships 21

Lonza and Massachusetts Eye and Ear Infirmary Enter into Licensing Agreement with Akouos 21

BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 22

Synpromics Enters into Partnership with Lonza 23

Lonza Enters into Agreement with Denali Therapeutics 24

Capsugel Enters into Agreement with Pulmatrix 25

Lonza Enters into Agreement with Kodiak Sciences 26

CiMaas Enters into Agreement with PharmaCell 27

Lonza Partners with Octane Biotech 28

Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29

Lonza and AMYRA Biotech Enter into Agreement 30

Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31

Catalent Pharma Solutions Enters Into Agreement With Bend Research 32

CSIRO Enters Into Co-Development Agreement With Lonza 33

Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34

Licensing Agreements 35

Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 35

CytoDyn Enters into Licensing Agreement with Lonza Sales 36

Leap Therapeutics Enters into Licensing Agreement with Lonza Sales 37

Xbiotech Enters Into Licensing Agreement With Lonza Sales 38

Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 39

Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 41

Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 42

Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 43

Pierre Fabre Enters into Licensing Agreement with Lonza 44

Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 45

Pierre Fabre Enters into Licensing Agreement with Lonza 46

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 47

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 48

Lonza Enters into Licensing Agreement with arGEN-X 50

Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 51

Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 52

Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 53

Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 54

Equity Offering 55

Lonza Raise USD2.24 Billion in Rights Offering of Shares 55

Lonza Raises USD871 Million in Private Placement of Shares 56

Debt Offering 57

Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 57

Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For USD 316.5 Million 58

Lonza Completes Public Offering Of Bonds Due 2022 For USD 112 Million 59

Lonza Completes Public Offering Of Bonds Due 2018 For USD 213 Million 60

Asset Transactions 61

PolyPeptide Acquires Peptides Business and Operations in Braine, Belgium from Lonza 61

Acquisition 62

Lonza Group Acquires micromacinazione from Cross 62

Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 63

Lonza Group Acquires PharmaCell 65

Lonza Acquires HansaBioMed Life Sciences 66

Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 67

Lonza Acquires Triangle Research Labs from PBM Capital 68

Lonza May Acquire Catalent 69

Capsugel Acquires Xcelience 70

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 71

PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 72

Capsugel Acquires Bend Research 73

Capsugel Belgium Acquires Encap Drug Delivery 74

Lonza Group Ltd-Key Competitors 75

Lonza Group Ltd-Key Employees 76

Lonza Group Ltd-Locations And Subsidiaries 77

Head Office 77

Other Locations & Subsidiaries 77

Joint Venture 80

Recent Developments 81

Strategy And Business Planning 81

Nov 05, 2018: Lonza expands capabilities for Parenteral Dosage Forms 81

Oct 08, 2018: Lonza expands HPAPI Development and Manufacturing Capacity for ADC Payloads 82

Sep 20, 2018: Lonza expands IbexsSolutions to offer complete product lifecycle management in one location 83

Sep 12, 2018: Lonza Breaks Ground on Expanded Manufacturing Facility in Greenwood, SC (USA) 84

May 02, 2018: Lonza Consumer Health and Nutrition Invests in Greenwood, SC (USA) Facility to Expand Specialty Ingredients Production 85

Feb 27, 2018: Lonza Group Inaugurates New Research and Development Center for South America in Salto, Brazil 86

Feb 14, 2018: Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth 87

Aug 24, 2017: Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms 88

Financial Announcements 89

Jul 25, 2018: Lonza reports strong momentum with organic growth of 8% sales and 11% CORE EBITDA in H1 2018 89

May 04, 2018: Lonza Reports Positive Start to 2018 with Businesses Along the Healthcare Continuum as Growth Drivers 92

Jan 31, 2018: Lonza Reports Record-Breaking Full-Year Results with Double-Digit Lonza Standalone Sales Growth and More than 26% CORE EBIT Growth in a Major Transformational Year 94

Oct 26, 2017: Lonza Reports a Strong Third Quarter and Capsugel Integration on Track 98

Jul 26, 2017: Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid-Term Growth 100

Jan 25, 2017: Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech 102

Corporate Communications 104

Jun 27, 2017: Lonza's CHRO Elected to Board of Advance Women in Swiss Business 104

Jan 25, 2017: Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 105

Government and Public Interest 106

Oct 09, 2018: Lonza to Host New Webinar-Streamlining Your QC Testing: Automated Endotoxin Testing and Process Optimization 106

Product News 107

Nov 08, 2017: Lonza Launches XS Pichia 2.0 Expression and Manufacturing Platform for Development of Next Generation Therapeutics 107

Oct 29, 2018: Lonza to launch XPressEV bioactive functional for the appearance of firmer, fitter skin at in-cosmetics Asia 108

Oct 23, 2018: Lonza's Capsule Delivery Solutions launches Capsugel Colorista 110

Sep 06, 2018: Lonza releases new technical note: Construction of a Full-Thickness Skin Model Using RAFT 3D Cell Culture System 111

Aug 29, 2018: Lonza's Capsule Delivery Solutions launches Capsugel Colorista 112

Jun 19, 2018: Lonza s Capsule Delivery Solutions Launches Capsugel Vcaps Gen C a New Specialty Polymer Capsule 113

May 22, 2018: Lonza Further Strengthens Hepatocytes Portfolio with Addition of Hepatic Non-Parenchymal Cells 114

Feb 15, 2018: Study Further Positions Lonza's UC-II A Undenatured Type II Collagen as a Leader in the Crowded Joint-Health Market 115

Other Significant Developments 116

Oct 25, 2018: Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year 116

Sep 25, 2018: Lonza's Capital Markets Day 2018 outlines sustainable growth plans through focus and investment 118

Sep 14, 2018: Lonza launches early-intermediates supply initiative for small-molecule APIs 119

Jul 02, 2018: Lonza Launches New Bioscience Website 120

May 04, 2018: Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics 121

Mar 26, 2018: Lonza to Host New Webinar: Integrating Devices into Quality Systems 122

Feb 20, 2018: Lonza Expands Encapsulation and HPAPI Capabilities in North America 123

Dec 14, 2017: Serialization Capabilities Now Operational at Lonza Edinburgh Facility for Liquid-Filled Hard Capsules 124

Appendix 126

Methodology 126

About GlobalData 126

Contact Us 126

Disclaimer 126


List Of Figure

List of Figures

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Lonza Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Lonza Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Lonza to Acquire Mammalian Manufacturing Site from Shire 16

Capsugel Acquires Ionic Liquids Technology from Monash University 17

InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18

Odyssey Thera Raises USD 3 Million In Venture Financing 19

Kainos Capital Acquires InterHealth Nutraceuticals 20

Lonza and Massachusetts Eye and Ear Infirmary Enter into Licensing Agreement with Akouos 21

BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 22

Synpromics Enters into Partnership with Lonza 23

Lonza Enters into Agreement with Denali Therapeutics 24

Capsugel Enters into Agreement with Pulmatrix 25

Lonza Enters into Agreement with Kodiak Sciences 26

CiMaas Enters into Agreement with PharmaCell 27

Lonza Partners with Octane Biotech 28

Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29

Lonza and AMYRA Biotech Enter into Agreement 30

Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31

Catalent Pharma Solutions Enters Into Agreement With Bend Research 32

CSIRO Enters Into Co-Development Agreement With Lonza 33

Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34

Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 35

CytoDyn Enters into Licensing Agreement with Lonza Sales 36

Leap Therapeutics Enters into Licensing Agreement with Lonza Sales 37

Xbiotech Enters Into Licensing Agreement With Lonza Sales 38

Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 39

Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 41

Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 42

Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 43

Pierre Fabre Enters into Licensing Agreement with Lonza 44

Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 45

Pierre Fabre Enters into Licensing Agreement with Lonza 46

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 47

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 48

Lonza Enters into Licensing Agreement with arGEN-X 50

Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 51

Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 52

Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 53

Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 54

Lonza Raise USD2.24 Billion in Rights Offering of Shares 55

Lonza Raises USD871 Million in Private Placement of Shares 56

Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 57

Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For USD 316.5 Million 58

Lonza Completes Public Offering Of Bonds Due 2022 For USD 112 Million 59

Lonza Completes Public Offering Of Bonds Due 2018 For USD 213 Million 60

PolyPeptide Acquires Peptides Business and Operations in Braine, Belgium from Lonza 61

Lonza Group Acquires micromacinazione from Cross 62

Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 63

Lonza Group Acquires PharmaCell 65

Lonza Acquires HansaBioMed Life Sciences 66

Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 67

Lonza Acquires Triangle Research Labs from PBM Capital 68

Lonza May Acquire Catalent 69

Capsugel Acquires Xcelience 70

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 71

PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 72

Capsugel Acquires Bend Research 73

Capsugel Belgium Acquires Encap Drug Delivery 74

Lonza Group Ltd, Key Competitors 75

Lonza Group Ltd, Key Employees 76

Lonza Group Ltd, Subsidiaries 77

Lonza Group Ltd, Joint Venture 80

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Lonza Group Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic personal care ingredients. It also provides custom development and custom manufacturing services to its clients. Lonza's client base includes professionals in the biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; distributors; formulators and service companies. The company's key markets include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care industries. It operates several manufacturing and research and development (R&D) facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd (LONN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Lonza to Acquire Mammalian Manufacturing Site from Shire 16

Capsugel Acquires Ionic Liquids Technology from Monash University 17

InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18

Venture Financing 19

Odyssey Thera Raises USD 3 Million In Venture Financing 19

Private Equity 20

Kainos Capital Acquires InterHealth Nutraceuticals 20

Partnerships 21

Lonza and Massachusetts Eye and Ear Infirmary Enter into Licensing Agreement with Akouos 21

BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 22

Synpromics Enters into Partnership with Lonza 23

Lonza Enters into Agreement with Denali Therapeutics 24

Capsugel Enters into Agreement with Pulmatrix 25

Lonza Enters into Agreement with Kodiak Sciences 26

CiMaas Enters into Agreement with PharmaCell 27

Lonza Partners with Octane Biotech 28

Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29

Lonza and AMYRA Biotech Enter into Agreement 30

Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31

Catalent Pharma Solutions Enters Into Agreement With Bend Research 32

CSIRO Enters Into Co-Development Agreement With Lonza 33

Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34

Licensing Agreements 35

Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 35

CytoDyn Enters into Licensing Agreement with Lonza Sales 36

Leap Therapeutics Enters into Licensing Agreement with Lonza Sales 37

Xbiotech Enters Into Licensing Agreement With Lonza Sales 38

Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 39

Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 41

Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 42

Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 43

Pierre Fabre Enters into Licensing Agreement with Lonza 44

Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 45

Pierre Fabre Enters into Licensing Agreement with Lonza 46

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 47

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 48

Lonza Enters into Licensing Agreement with arGEN-X 50

Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 51

Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 52

Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 53

Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 54

Equity Offering 55

Lonza Raise USD2.24 Billion in Rights Offering of Shares 55

Lonza Raises USD871 Million in Private Placement of Shares 56

Debt Offering 57

Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 57

Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For USD 316.5 Million 58

Lonza Completes Public Offering Of Bonds Due 2022 For USD 112 Million 59

Lonza Completes Public Offering Of Bonds Due 2018 For USD 213 Million 60

Asset Transactions 61

PolyPeptide Acquires Peptides Business and Operations in Braine, Belgium from Lonza 61

Acquisition 62

Lonza Group Acquires micromacinazione from Cross 62

Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 63

Lonza Group Acquires PharmaCell 65

Lonza Acquires HansaBioMed Life Sciences 66

Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 67

Lonza Acquires Triangle Research Labs from PBM Capital 68

Lonza May Acquire Catalent 69

Capsugel Acquires Xcelience 70

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 71

PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 72

Capsugel Acquires Bend Research 73

Capsugel Belgium Acquires Encap Drug Delivery 74

Lonza Group Ltd-Key Competitors 75

Lonza Group Ltd-Key Employees 76

Lonza Group Ltd-Locations And Subsidiaries 77

Head Office 77

Other Locations & Subsidiaries 77

Joint Venture 80

Recent Developments 81

Strategy And Business Planning 81

Nov 05, 2018: Lonza expands capabilities for Parenteral Dosage Forms 81

Oct 08, 2018: Lonza expands HPAPI Development and Manufacturing Capacity for ADC Payloads 82

Sep 20, 2018: Lonza expands IbexsSolutions to offer complete product lifecycle management in one location 83

Sep 12, 2018: Lonza Breaks Ground on Expanded Manufacturing Facility in Greenwood, SC (USA) 84

May 02, 2018: Lonza Consumer Health and Nutrition Invests in Greenwood, SC (USA) Facility to Expand Specialty Ingredients Production 85

Feb 27, 2018: Lonza Group Inaugurates New Research and Development Center for South America in Salto, Brazil 86

Feb 14, 2018: Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth 87

Aug 24, 2017: Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms 88

Financial Announcements 89

Jul 25, 2018: Lonza reports strong momentum with organic growth of 8% sales and 11% CORE EBITDA in H1 2018 89

May 04, 2018: Lonza Reports Positive Start to 2018 with Businesses Along the Healthcare Continuum as Growth Drivers 92

Jan 31, 2018: Lonza Reports Record-Breaking Full-Year Results with Double-Digit Lonza Standalone Sales Growth and More than 26% CORE EBIT Growth in a Major Transformational Year 94

Oct 26, 2017: Lonza Reports a Strong Third Quarter and Capsugel Integration on Track 98

Jul 26, 2017: Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid-Term Growth 100

Jan 25, 2017: Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech 102

Corporate Communications 104

Jun 27, 2017: Lonza's CHRO Elected to Board of Advance Women in Swiss Business 104

Jan 25, 2017: Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 105

Government and Public Interest 106

Oct 09, 2018: Lonza to Host New Webinar-Streamlining Your QC Testing: Automated Endotoxin Testing and Process Optimization 106

Product News 107

Nov 08, 2017: Lonza Launches XS Pichia 2.0 Expression and Manufacturing Platform for Development of Next Generation Therapeutics 107

Oct 29, 2018: Lonza to launch XPressEV bioactive functional for the appearance of firmer, fitter skin at in-cosmetics Asia 108

Oct 23, 2018: Lonza's Capsule Delivery Solutions launches Capsugel Colorista 110

Sep 06, 2018: Lonza releases new technical note: Construction of a Full-Thickness Skin Model Using RAFT 3D Cell Culture System 111

Aug 29, 2018: Lonza's Capsule Delivery Solutions launches Capsugel Colorista 112

Jun 19, 2018: Lonza s Capsule Delivery Solutions Launches Capsugel Vcaps Gen C a New Specialty Polymer Capsule 113

May 22, 2018: Lonza Further Strengthens Hepatocytes Portfolio with Addition of Hepatic Non-Parenchymal Cells 114

Feb 15, 2018: Study Further Positions Lonza's UC-II A Undenatured Type II Collagen as a Leader in the Crowded Joint-Health Market 115

Other Significant Developments 116

Oct 25, 2018: Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year 116

Sep 25, 2018: Lonza's Capital Markets Day 2018 outlines sustainable growth plans through focus and investment 118

Sep 14, 2018: Lonza launches early-intermediates supply initiative for small-molecule APIs 119

Jul 02, 2018: Lonza Launches New Bioscience Website 120

May 04, 2018: Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics 121

Mar 26, 2018: Lonza to Host New Webinar: Integrating Devices into Quality Systems 122

Feb 20, 2018: Lonza Expands Encapsulation and HPAPI Capabilities in North America 123

Dec 14, 2017: Serialization Capabilities Now Operational at Lonza Edinburgh Facility for Liquid-Filled Hard Capsules 124

Appendix 126

Methodology 126

About GlobalData 126

Contact Us 126

Disclaimer 126


List Of Figure

List of Figures

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Lonza Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Lonza Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Lonza to Acquire Mammalian Manufacturing Site from Shire 16

Capsugel Acquires Ionic Liquids Technology from Monash University 17

InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18

Odyssey Thera Raises USD 3 Million In Venture Financing 19

Kainos Capital Acquires InterHealth Nutraceuticals 20

Lonza and Massachusetts Eye and Ear Infirmary Enter into Licensing Agreement with Akouos 21

BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 22

Synpromics Enters into Partnership with Lonza 23

Lonza Enters into Agreement with Denali Therapeutics 24

Capsugel Enters into Agreement with Pulmatrix 25

Lonza Enters into Agreement with Kodiak Sciences 26

CiMaas Enters into Agreement with PharmaCell 27

Lonza Partners with Octane Biotech 28

Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29

Lonza and AMYRA Biotech Enter into Agreement 30

Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31

Catalent Pharma Solutions Enters Into Agreement With Bend Research 32

CSIRO Enters Into Co-Development Agreement With Lonza 33

Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34

Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 35

CytoDyn Enters into Licensing Agreement with Lonza Sales 36

Leap Therapeutics Enters into Licensing Agreement with Lonza Sales 37

Xbiotech Enters Into Licensing Agreement With Lonza Sales 38

Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 39

Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 41

Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 42

Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 43

Pierre Fabre Enters into Licensing Agreement with Lonza 44

Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 45

Pierre Fabre Enters into Licensing Agreement with Lonza 46

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 47

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 48

Lonza Enters into Licensing Agreement with arGEN-X 50

Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 51

Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 52

Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 53

Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 54

Lonza Raise USD2.24 Billion in Rights Offering of Shares 55

Lonza Raises USD871 Million in Private Placement of Shares 56

Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 57

Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For USD 316.5 Million 58

Lonza Completes Public Offering Of Bonds Due 2022 For USD 112 Million 59

Lonza Completes Public Offering Of Bonds Due 2018 For USD 213 Million 60

PolyPeptide Acquires Peptides Business and Operations in Braine, Belgium from Lonza 61

Lonza Group Acquires micromacinazione from Cross 62

Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 63

Lonza Group Acquires PharmaCell 65

Lonza Acquires HansaBioMed Life Sciences 66

Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 67

Lonza Acquires Triangle Research Labs from PBM Capital 68

Lonza May Acquire Catalent 69

Capsugel Acquires Xcelience 70

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 71

PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 72

Capsugel Acquires Bend Research 73

Capsugel Belgium Acquires Encap Drug Delivery 74

Lonza Group Ltd, Key Competitors 75

Lonza Group Ltd, Key Employees 76

Lonza Group Ltd, Subsidiaries 77

Lonza Group Ltd, Joint Venture 80

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Lonza Group Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.